Delivery Order SPE2DB22D3501-SPE2DB25FWU59
Award Date 8/11/25
Potential Completion Date 9/2/25
Potential Value $25K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $24,673.08 delivery order to AmerisourceBergen Drug Corp for Hemlibra 105 mg/0.7 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. Hemlibra is a specialized biopharmaceutical used in the treatment of hemophilia, reflecting the critical nature of pharmaceutical procurement for military and federal healthcare systems. The place of performance is AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,673.08 to AmerisourceBergen Drug Corp for the supply of Hemlibra 105 mg/0.7 mL vials. This firm fixed-price, non-set-aside contract was executed on May 30, 2025, with an ultimate completion date of June 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Hemlibra is a bispecific monoclonal antibody used in the treatment of hemophilia A and B, representing a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of HEMLIBRA 105 mg/0.7 mL vials totaling $6,168.26. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award authority. The order is scheduled for completion by August 29, 2025, with performance taking place at AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania. HEMLIBRA is a specialty pharmaceutical product...
- The Defense Logistics Agency awarded a $24,673.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEMLIBRA 105 mg/0.7 ml vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEMLIBRA is a specialty pharmaceutical product used in hemophilia treatment, reflecting the federal government's need for advanced therapeutic...
- The Defense Logistics Agency awarded a delivery order valued at $26,451.57 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 150 mg/ml vials. This firm fixed price contract, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the pharmaceutical distributor maintains its...
- The Defense Logistics Agency awarded a $35,268.76 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of HEMLIBRA 150 mg/ml vials. This non-competitive delivery order, with an ultimate completion date of June 3, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 master pharmaceutical supply vehicle running through December 2026. The performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,673.08 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 105 mg/0.7 ml vials. This is a firm fixed-price, non-set-aside contract with a completion date of August 8, 2025, and was awarded on July 18, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order operates under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,673.08, is for the supply of 4567331942 HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a specialty medication. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,673.08 firm fixed-price delivery order is for the supply of HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a specialty pharmaceutical product. The contract has an ultimate completion date of April 29, 2025 and was awarded on April 8, 2025. This contract award is a part of a larger Indefinite Delivery Contract (IDC) valued...
- This federal contract award, valued at $16,704.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of HEMLIBRA 150 MG/ML VIALML. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of August 5, 2024. Amerisourcebergen Drug Corp, through its Corporate Office Division, has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...